Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M4rQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwNkGyN|ch|ryP NF\OT41USU6JRWK=
H4 NIPHe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\DW5hKSzVyPUCuOlYzQCEQvF2= NIWwcmJUSU6JRWK=
PA-1 NHTGXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vMUmlEPTB;MD64O|A6PiEQvF2= NGPXRpdUSU6JRWK=
NKM-1 M1rQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\iVGlEPTB;MT6wOFk{OSEQvF2= NWnlWpNvW0GQR1XS
NEC8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jrVGlEPTB;MT6yNVU4OiEQvF2= NEH4UlZUSU6JRWK=
EoL-1-cell MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f2R2lEPTB;MT6yOlcxOSEQvF2= MVHTRW5ITVJ?
K5 NFnDVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXuTWM2OD1zLkSyNFczKM7:TR?= M{fnbHNCVkeHUh?=
QIMR-WIL NVzodGRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW2[pZ6UUN3ME2xMlYxQDV2IN88US=> NX3ocmVDW0GQR1XS
MOLT-16 NFvueXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TaR2lEPTB;MT63PFYxPCEQvF2= NEPCTm1USU6JRWK=
CHP-212 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfFTWM2OD1zLkixN|Y6KM7:TR?= MnO5V2FPT0WU
CTB-1 NYjFbnAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWzUVVLUUN3ME2yMlAzOjR4IN88US=> Mm\uV2FPT0WU
MOLT-4 NH76WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJwM{K4OVMh|ryP NYqwU21SW0GQR1XS
A101D MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XhXWlEPTB;Mj6zOVAyKM7:TR?= Mlf2V2FPT0WU
DOHH-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PBWmlEPTB;Mj60NlI4QSEQvF2= NHPicGNUSU6JRWK=
ES4 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1{LkSzNVU2KM7:TR?= MkDJV2FPT0WU
SW780 M3fuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2naTWlEPTB;Mj61NFg5OyEQvF2= NYC0cmhxW0GQR1XS
VA-ES-BJ Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLSSVNKUUN3ME2yMlU1OTFizszN MWXTRW5ITVJ?
RPMI-8866 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XFd2lEPTB;Mj61OlIyPCEQvF2= MVPTRW5ITVJ?
ML-2 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPDfFFIUUN3ME2yMlU3PTd4IN88US=> NH7Fdm1USU6JRWK=
MSTO-211H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq0TWM2OD1{LkW3OFUyKM7:TR?= Mo[2V2FPT0WU
JVM-3 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwNUmzNlQh|ryP NG\afI9USU6JRWK=
A3-KAW M1iyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHlSZRKSzVyPUKuOlE5OThizszN MlruV2FPT0WU
DK-MG NXnyVoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjvdHluUUN3ME2yMlYzPDdzIN88US=> NXPvbGhCW0GQR1XS
LNCaP-Clone-FGC NXW2PZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliyTWM2OD1{Lk[0N|E5KM7:TR?= NHvVRWZUSU6JRWK=
HT-144 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwNkS1O|ch|ryP NXTFV4NEW0GQR1XS
NB69 NVj6UGRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;W[o9IUUN3ME2yMlY2OzN2IN88US=> NH\HWllUSU6JRWK=
A172 NU\h[XV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDidFRKSzVyPUKuOlc2QDhizszN M{nXTnNCVkeHUh?=
RS4-11 M3zlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fZdGlEPTB;Mj63NlQxPyEQvF2= MYjTRW5ITVJ?
DU-4475 M4HlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH6TWM2OD1{Lke5OVAzKM7:TR?= M3LNfHNCVkeHUh?=
SJSA-1 NYfaR2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj0WW1DUUN3ME2yMlgzPTV4IN88US=> Ml3pV2FPT0WU
BV-173 NXXYVmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq5TWM2OD1{Lki0OFM6KM7:TR?= NGT4UmVUSU6JRWK=
U-2-OS M2XtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW3cmlWUUN3ME2yMlkyODdizszN NFjvcVlUSU6JRWK=
CHP-134 NXS4VYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCXI56UUN3ME2yMlk{QDh{IN88US=> MYrTRW5ITVJ?
D-502MG MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13RTGlEPTB;Mj65O|E2PCEQvF2= MmLOV2FPT0WU
KS-1 M3fBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwMEG2NlMh|ryP MlviV2FPT0WU
A204 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HWVGlEPTB;Mz6wOVU5QCEQvF2= Mn;ZV2FPT0WU
KGN MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNwMEi0PVYh|ryP MXvTRW5ITVJ?
NCI-H292 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHsepZqUUN3ME2zMlEzODJ6IN88US=> MWfTRW5ITVJ?
CAKI-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jxfmlEPTB;Mz6xNlY6PCEQvF2= MUHTRW5ITVJ?
C2BBe1 NXnPcWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3HTWM2OD1|LkG3NFI3KM7:TR?= NX;mNJp5W0GQR1XS
NB10 M2j4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLDe2tKSzVyPUOuNlA6PjZizszN NGriO|RUSU6JRWK=
MHH-NB-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXs[nNKSzVyPUOuNlY5OjdizszN M2LEXXNCVkeHUh?=
NCI-SNU-1 NGW5fmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DnXmlEPTB;Mz6yO|g1OyEQvF2= NY\uU2JUW0GQR1XS
HCT-116 NFrzSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G2c2lEPTB;Mz6zNFM{PSEQvF2= NFHqSWpUSU6JRWK=
G-401 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37XfmlEPTB;Mz6zOlMzOiEQvF2= M4XLZnNCVkeHUh?=
MN-60 M4fROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHBSHhkUUN3ME2zMlQ1ODl{IN88US=> NWjRRoZwW0GQR1XS
SW982 NGW4O4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG4R2NKSzVyPUOuOVA5PDhizszN M1ThTHNCVkeHUh?=
RKO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwNUO5N|Yh|ryP M1rHe3NCVkeHUh?=
D-283MED M3HMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrWG1KSzVyPUOuOVc6QDZizszN MXTTRW5ITVJ?
LB996-RCC NYTEbJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHYTWM2OD1|Lk[yOVU5KM7:TR?= MXXTRW5ITVJ?
A549 M3;sSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwNkO1OVIh|ryP M1nMTHNCVkeHUh?=
LB2241-RCC NHPjc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf2TWM2OD1|Lk[1O|A5KM7:TR?= MnHqV2FPT0WU
SK-HEP-1 NELqeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPoWXEyUUN3ME2zMlc1Ojl5IN88US=> M1HYOXNCVkeHUh?=
G-402 M4C1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvYbZVbUUN3ME2zMlgxQDN{IN88US=> MWLTRW5ITVJ?
GOTO NUH4PYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr2V5M4UUN3ME2zMlg1OzN|IN88US=> NXO4UZptW0GQR1XS
LOXIMVI MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ZZ4szUUN3ME2zMlg2Pjd3IN88US=> MWnTRW5ITVJ?
NH-12 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrvTWM2OD12LkCxPVU6KM7:TR?= M{TwRnNCVkeHUh?=
CTV-1 M1TkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjXfVhKSzVyPUSuNFc6PzNizszN MluxV2FPT0WU
CP50-MEL-B NVvubJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hjb2lEPTB;ND6yOFM6OiEQvF2= MUfTRW5ITVJ?
RH-18 NFXWeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDTU2ZKSzVyPUSuNlc4ODZizszN MlLlV2FPT0WU
NB17 NEn5UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzBdmJKSzVyPUSuN|E4PjhizszN M1LLbXNCVkeHUh?=
A375 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjx[WlKSzVyPUSuN|M2OjRizszN NWrzO2NkW0GQR1XS
IST-MES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISxe|dKSzVyPUSuOFE1OTFizszN NHTZS41USU6JRWK=
MZ2-MEL NX7keJAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17HOGlEPTB;ND61NFE2PSEQvF2= NGXQSotUSU6JRWK=
CAL-54 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnI[ZFKSzVyPUSuOVMxOTlizszN NUHadVRQW0GQR1XS
NCI-H28 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwNkK3NVch|ryP NX\vcWw2W0GQR1XS
D-247MG NXTmNFlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwN{WwO|Ih|ryP NEHvbI1USU6JRWK=
NCI-H460 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwOUGxNlch|ryP M3HROHNCVkeHUh?=
MCF7 NVjPUlF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr5R49KSzVyPUWuOFQzPDRizszN MYTTRW5ITVJ?
697 NYC4TZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTVwNES1OUDPxE1? NHnpVHFUSU6JRWK=
ONS-76 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf2e4hKSzVyPUWuOVcxODlizszN MYfTRW5ITVJ?
C32 NVnX[ot7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\wSJdKSzVyPUWuOlAxOjlizszN NHHzSGVUSU6JRWK=
OS-RC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnMTWM2OD13LkezPFg4KM7:TR?= NHWwOohUSU6JRWK=
MEL-HO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTVwOEW2Olch|ryP NHTlW|FUSU6JRWK=
LoVo M3;qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP3TWM2OD14LkCxOlI1KM7:TR?= M2m3UXNCVkeHUh?=
AGS MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm5ZWFtUUN3ME22MlE1QDJ6IN88US=> NXT5eZdPW0GQR1XS
GI-ME-N NGDxNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHMTWM2OD14LkKyOFIyKM7:TR?= MVLTRW5ITVJ?
H-EMC-SS M3i1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nHfmlEPTB;Nj6zPFYh|ryP M2XlN3NCVkeHUh?=
RVH-421 NInXepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HzWWlEPTB;Nj60NlQzQCEQvF2= NEfJdGNUSU6JRWK=
SW954 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\pTWM2OD14LkW1OVczKM7:TR?= M1XMcHNCVkeHUh?=
NB5 NWPDc4sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHGTWM2OD14LkW2NVg{KM7:TR?= M1vsXXNCVkeHUh?=
NCI-H2122 M2fVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD14LkW4O|k{KM7:TR?= MVHTRW5ITVJ?
AM-38 NIDW[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTXTWM2OD14Lke1OlM6KM7:TR?= NHXlNXBUSU6JRWK=
KNS-81-FD M17OSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH5VI1KSzVyPU[uO|Y1QTRizszN MX7TRW5ITVJ?
LS-513 M4Tl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCyNXhWUUN3ME22Mlc6ODJ4IN88US=> NFnQSopUSU6JRWK=
A427 NWDtVXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXl[HNKSzVyPU[uPFc5OjlizszN MWLTRW5ITVJ?
WM-115 M3\0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[5cWxKSzVyPU[uPVMzOyEQvF2= NF30O3ZUSU6JRWK=
COLO-829 M3TON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[yTWM2OD15LkK0NVg5KM7:TR?= NHjqcXVUSU6JRWK=
NCI-H1650 M4jFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H0N2lEPTB;Nz6zPVIzQCEQvF2= NU\MWHoyW0GQR1XS
NCI-H358 NF7VSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\yOnJNUUN3ME23MlQ1QDd7IN88US=> M4PhVXNCVkeHUh?=
HT-1080 NFK0fWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTJTWM2OD15LkS4NlU1KM7:TR?= M3m1U3NCVkeHUh?=
HCC2218 M{XmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnO[I5KSzVyPUeuOlI6PyEQvF2= MkTSV2FPT0WU
NCI-H661 M{PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP5dYlKSzVyPUeuPFcxPjlizszN MX\TRW5ITVJ?
KM-H2 M1mxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LK[WlEPTB;Nz64PFY6PCEQvF2= MWfTRW5ITVJ?
RPMI-2650 NHTPfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHWRYhRUUN3ME23Mlk1PDF2IN88US=> NGjoXnRUSU6JRWK=
NCI-H226 NGGyWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELNcnFKSzVyPUiuNlEyOjJizszN MlXXV2FPT0WU
MKN45 NIHiUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S2UWlEPTB;OD6yOlYxOiEQvF2= NGnidmNUSU6JRWK=
D-392MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKPWRCUUN3ME24MlUzPzJ{IN88US=> NX7i[HNSW0GQR1XS
RCC10RGB NGXWOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXTTWM2OD16Lki2Olk2KM7:TR?= MonNV2FPT0WU
CAL-51 NXTWR5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TtXWlEPTB;OT6xNFI2OSEQvF2= M2noUXNCVkeHUh?=
COLO-678 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljDTWM2OD17LkOyPFEyKM7:TR?= MmL4V2FPT0WU
SK-MEL-24 M4PnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\IS2lEPTB;OT61OVg2PiEQvF2= NF3ZT5BUSU6JRWK=
SK-MEL-30 NXzzRoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwOUS0O|Yh|ryP M4LsOXNCVkeHUh?=
MMAC-SF MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDvd4pWUUN3ME2xNE4{QTZzIN88US=> Ml\0V2FPT0WU
NTERA-S-cl-D1 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPhTWM2OD1zMD62OVA5KM7:TR?= NFn0OWdUSU6JRWK=
NB12 NGH5OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTtTYNKSzVyPUGxMlUxOyEQvF2= M4r2cnNCVkeHUh?=
UACC-257 NX3m[moyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfvTWM2OD1zMT64Olk2KM7:TR?= MVzTRW5ITVJ?
LAN-6 NVLndmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPqTWM2OD1zMT65PVI5KM7:TR?= MoHrV2FPT0WU
SW1573 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;aXJhKSzVyPUGyMlMxQDZizszN M1TubHNCVkeHUh?=
NMC-G1 M2D5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF{LkSxO|Uh|ryP NIfrdmtUSU6JRWK=
SHP-77 M4T5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD1zMj61OVc1KM7:TR?= MWjTRW5ITVJ?
IGROV-1 NIL2[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrse4tMUUN3ME2xNk43PTd|IN88US=> M1PIRXNCVkeHUh?=
22RV1 NWD0UJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvTWM2OD1zMj64NFU6KM7:TR?= Mlj6V2FPT0WU
SK-MEL-3 NHfiPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HyNGlEPTB;MUOuN|k4OyEQvF2= Mn;1V2FPT0WU
NCI-H1563 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DYbWlEPTB;MUOuOFIxOiEQvF2= NFfXdlJUSU6JRWK=
IGR-1 M3LvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;5TWM2OD1zND6wN|Q4KM7:TR?= MVvTRW5ITVJ?
EW-3 NUjPUoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGyTFdKUUN3ME2xOE4yPjN7IN88US=> NIfvdYlUSU6JRWK=
JEG-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHsTWM2OD1zND60PVU{KM7:TR?= NHjuO3ZUSU6JRWK=
ES3 NXXxNnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv3TWFKSzVyPUG0MlY2PjJizszN MmT5V2FPT0WU
MDA-MB-175-VII MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULPUHhNUUN3ME2xOE44OTFzIN88US=> MYHTRW5ITVJ?
P30-OHK NV[3OoNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF3LkC0PVYh|ryP MV\TRW5ITVJ?
GP5d MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF3LkG0OlYh|ryP NF\UbI5USU6JRWK=
HMV-II Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF3LkOzN|Mh|ryP MkXhV2FPT0WU
COLO-679 NGH2NnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF3LkWwNUDPxE1? Ml;yV2FPT0WU
JAR M{Gz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnEPFFKSzVyPUG1MlczODVizszN M2T0W3NCVkeHUh?=
NCI-H1666 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWwNYt{UUN3ME2xOU46Ozl7IN88US=> MVLTRW5ITVJ?
SW48 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\tNlFEUUN3ME2xOU46PTF4IN88US=> Mn[0V2FPT0WU
NCI-H720 NWDvems2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDsV2xKSzVyPUG1Mlk6QDlizszN NInzdHVUSU6JRWK=
HT-1197 NFTwenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXJb3VGUUN3ME2xOk4xOzV{IN88US=> MoPmV2FPT0WU
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrITWM2OD1zNj6wN|g1KM7:TR?= NUXQS|dQW0GQR1XS
BEN MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XiUGlEPTB;MU[uOVY{QCEQvF2= NUTTOld6W0GQR1XS
HAL-01 M2XPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPFTWM2OD1zNj64PVA6KM7:TR?= NWfldIQ4W0GQR1XS
SW900 M2jxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\hTWM2OD1zNj65NVMzKM7:TR?= M2Djd3NCVkeHUh?=
SBC-1 M{L2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDjc4pKSzVyPUG3MlU1OjlizszN NHv1e4FUSU6JRWK=
SH-4 NIHMNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF5LkW4OFEh|ryP NHqxSJlUSU6JRWK=
UACC-62 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjUTWM2OD1zNz63OlM4KM7:TR?= NEnjcVVUSU6JRWK=
BHT-101 M3nFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXuTWM2OD1zOT64O|A2KM7:TR?= MnfJV2FPT0WU
DB M1K5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXUTWM2OD1{MT61OlQ6KM7:TR?= M{nBOHNCVkeHUh?=
SK-MEL-1 NYfMNmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJzLkW4O|Ih|ryP NV\FTHlbW0GQR1XS
NCI-H747 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfh[JZHUUN3ME2yNk44Ozd7IN88US=> MWnTRW5ITVJ?
SK-LU-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn0TWM2OD1{Mz6zOVI1KM7:TR?= NV7EN3h{W0GQR1XS
KG-1 NWTkXHFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GzRWlEPTB;MkOuOFk1PiEQvF2= MYrTRW5ITVJ?
LXF-289 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSTpRKSzVyPUKzMlcyPCEQvF2= NGXjdXJUSU6JRWK=
HCC1954 M4Phc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG4TWM2OD1{ND64PFQ1KM7:TR?= M2\nT3NCVkeHUh?=
Ramos-2G6-4C10 NHP0NGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO0N49KSzVyPUK2MlQ6QDFizszN NIXSXI5USU6JRWK=
DBTRG-05MG M2SyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:yPYdKSzVyPUK2MlY1QDhizszN MWjTRW5ITVJ?
NCI-H2052 NXnFe5NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTjOoU3UUN3ME2yO{42Pjh2IN88US=> NUjjN45wW0GQR1XS
RMG-I NF3ncXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rTd2lEPTB;MkmuOFE{QSEQvF2= M3u4XXNCVkeHUh?=
H9 NXPXdXMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH65ZYxKSzVyPUOxMlMxODhizszN Mk\uV2FPT0WU
GR-ST NYLKS3FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;DTWM2OD1|Mj60OFU{KM7:TR?= M2XNeXNCVkeHUh?=
Mo-T NULLVYZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN{LkWwOFYh|ryP MXzTRW5ITVJ?
SW1088 M1fseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN{Lkm4NFEh|ryP MYHTRW5ITVJ?
LB2518-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljNTWM2OD1|Mz6wO|k4KM7:TR?= NXnaRVI4W0GQR1XS
NCI-H82 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN|LkG2OlEh|ryP MYTTRW5ITVJ?
LAMA-84 NGLXTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfUNlRKSzVyPUO0MlYxPzNizszN M3HpN3NCVkeHUh?=
KYSE-450 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX5TWM2OD1|ND62O|c3KM7:TR?= MmrxV2FPT0WU
LU-99A NYO0WZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL0TWM2OD1|NT6wNFA4KM7:TR?= NHu0c5JUSU6JRWK=
BE-13 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjzcnNKSzVyPUO1MlY2PDVizszN NV\XNWJLW0GQR1XS
GAK NEHYT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzCUYhKUUN3ME2zOU43QTVizszN NXnJPZlYW0GQR1XS
NCI-H1573 NX7HT4NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN3Lki4NVgh|ryP M1TC[nNCVkeHUh?=
AsPC-1 NHzt[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvqTWM2OD1|Nj6xOVI4KM7:TR?= NYm0OnhsW0GQR1XS
HDLM-2 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn73TWM2OD1|Nj6zNVYh|ryP NEH6[4ZUSU6JRWK=
NCI-H441 M3TFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXSOXduUUN3ME2zO{4xPjlzIN88US=> NUO3SpVWW0GQR1XS
CAL-27 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPx[4ZKSzVyPUO3MlczOzFizszN MlzsV2FPT0WU
OVCAR-3 NVfmZpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXWTWM2OD1|OT6zNVgyKM7:TR?= M4LtdXNCVkeHUh?=
RPMI-8226 NFTFcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzu[IdKSzVyPUO5MlU6QCEQvF2= NIjpdItUSU6JRWK=
EFO-21 M3KyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrUfWJKSzVyPUSwMlU5OTRizszN MnjaV2FPT0WU
SNU-C2B MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PIOGlEPTB;NEGuOVA5PCEQvF2= M{TEdnNCVkeHUh?=
VM-CUB-1 NVn3dIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;zSo1KSzVyPUSzMlgxOzdizszN MWDTRW5ITVJ?
NCI-H2087 NFHYVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rTZmlEPTB;NEWuNFI{OyEQvF2= MVzTRW5ITVJ?
EW-16 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPab|JKSzVyPUS2MlMyOzdizszN NV3pbXBGW0GQR1XS
SK-N-AS MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhT2FoUUN3ME20Ok44OTZ5IN88US=> MXjTRW5ITVJ?
COR-L105 NGSxb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHlSYcxUUN3ME20Ok45QDV5IN88US=> MoiwV2FPT0WU
DEL M4S5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvFZYV5UUN3ME20PE4xPDJ7IN88US=> NEnrOW1USU6JRWK=
JVM-2 NUP5Z2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DYUWlEPTB;NEiuNFU2QCEQvF2= MVTTRW5ITVJ?
KARPAS-45 NGfadVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTZ[WpFUUN3ME20PU41PTN6IN88US=> NW\2R4RDW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL
In vivo 5% DMSO+55% PEG 300+ddH2O 8mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID